Chronic neutrophilic leukemia diagnostic study of choice: Difference between revisions
Jump to navigation
Jump to search
Homa Najafi (talk | contribs) |
m (Bot: Removing from Primary care) |
||
| (6 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Chronic neutrophilic leukemia}} | {{Chronic neutrophilic leukemia}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}} {{Homa}}; {{GRR}} {{Nat}} | ||
== Overview == | == Overview == | ||
[[World health organization]] [[(WHO)]] introduces [[criteria]] for the diagnosis of chronic neutrophilic leukemia (CNL) that are based on the [[laboratory]] finding of [[peripheral blood cells]], [[bone marrow]], cytogenic [[mutation]], and [[differential diagnosis]]. | [[World health organization]] [[(WHO)]] introduces [[criteria]] for the diagnosis of chronic neutrophilic leukemia (CNL) that are based on the [[laboratory]] finding of [[peripheral blood cells]], [[bone marrow]], cytogenic [[mutation]], and [[differential diagnosis]]. | ||
| Line 10: | Line 10: | ||
The [[diagnosis]] of CNL is based on the [[WHO]] criteria, which include:<ref name="ArberOrazi2016">{{cite journal|last1=Arber|first1=D. A.|last2=Orazi|first2=A.|last3=Hasserjian|first3=R.|last4=Thiele|first4=J.|last5=Borowitz|first5=M. J.|last6=Le Beau|first6=M. M.|last7=Bloomfield|first7=C. D.|last8=Cazzola|first8=M.|last9=Vardiman|first9=J. W.|title=The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia|journal=Blood|volume=127|issue=20|year=2016|pages=2391–2405|issn=0006-4971|doi=10.1182/blood-2016-03-643544}}</ref> | The [[diagnosis]] of CNL is based on the [[WHO]] criteria, which include:<ref name="ArberOrazi2016">{{cite journal|last1=Arber|first1=D. A.|last2=Orazi|first2=A.|last3=Hasserjian|first3=R.|last4=Thiele|first4=J.|last5=Borowitz|first5=M. J.|last6=Le Beau|first6=M. M.|last7=Bloomfield|first7=C. D.|last8=Cazzola|first8=M.|last9=Vardiman|first9=J. W.|title=The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia|journal=Blood|volume=127|issue=20|year=2016|pages=2391–2405|issn=0006-4971|doi=10.1182/blood-2016-03-643544}}</ref> | ||
{| | {| | ||
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |World Health Organization (WHO) Criteria for CNL diagnosis | |||
|- | |- | ||
! style="background: #DCDCDC; text-align: center;" |1. [[Peripheral blood]] [[White blood cells]][[(WBC)]] ≥25 | ! style="background: #DCDCDC; text-align: center;" |1. [[Peripheral blood]] [[White blood cells]] [[(WBC)]] ≥25 ×10<sup>9</sup>/L: | ||
| style="background: #F5F5F5;" | | | style="background: #F5F5F5;" | | ||
* Segmented [[neutrophils]] plus [[Band cell|band]] forms ≥80% of [[WBC]] | * Segmented [[neutrophils]] plus [[Band cell|band]] forms ≥80% of [[WBC]] | ||
* [[Neutrophil]] [[Precursor|precursors]] <10% of WBC | * [[Neutrophil]] [[Precursor|precursors]] <10% of WBC | ||
* [[Myeloblast|Myeloblasts]] rarely observed | * [[Myeloblast|Myeloblasts]] rarely observed | ||
* [[Monocyte]] count <1 ×10<sup>9</sup>/L | |||
* [[Monocyte]] count <1 | |||
* No dysgranulopoies. | * No dysgranulopoies. | ||
|- | |- | ||
| Line 29: | Line 24: | ||
| style="background: #F5F5F5;" | | | style="background: #F5F5F5;" | | ||
* [[Neutrophil granulocytes]] increased in percentage and number | * [[Neutrophil granulocytes]] increased in percentage and number | ||
* Normal [[neutrophil]] [[maturation]] | * Normal [[neutrophil]] [[maturation]] | ||
* [[Myeloblast|Myeloblasts]] <5% of [[nucleated]] cells | * [[Myeloblast|Myeloblasts]] <5% of [[nucleated]] cells | ||
|- | |- | ||
! style="background: #DCDCDC; text-align: center;" |3. Not meeting [[WHO]] criteria for: | ! style="background: #DCDCDC; text-align: center;" |3. Not meeting [[WHO]] criteria for: | ||
| style="background: #F5F5F5;" | | | style="background: #F5F5F5;" | | ||
* BCR-ABL1+ [[chronic myeloid leukemia]], | * BCR-ABL1+ [[chronic myeloid leukemia]], | ||
* [[Polycythemia vera]] | * [[Polycythemia vera]] | ||
* [[Essential thrombocythemia]] | * [[Essential thrombocythemia]] | ||
* [[Primary myelofibrosis]] | * [[Primary myelofibrosis]] | ||
|- | |- | ||
! style="background: #DCDCDC; text-align: center;" |4.No rearrangement of: | ! style="background: #DCDCDC; text-align: center;" |4. No rearrangement of: | ||
| | | style="background: #F5F5F5;" | | ||
* PDGFRA | * PDGFRA | ||
* [[PDGFRB]] | * [[PDGFRB]] | ||
| Line 50: | Line 41: | ||
* PCM1-JAK2 | * PCM1-JAK2 | ||
|- | |- | ||
! colspan="2" |5.Presence of CSF3RT618I or other activating [[CSF3R]] [[mutation]] or | ! colspan="2" style="background: #DCDCDC; text-align: center;" | | ||
In the absence of a CSFR3R [[Mutation|mutation,]] persistent [[neutrophilia]] (at least 3 months), [[splenomegaly]], and no identifiable cause of reactive [[neutrophilia]] | 5.Presence of CSF3RT618I or other activating [[CSF3R]] [[mutation]] or In the absence of a CSFR3R [[Mutation|mutation,]] persistent [[neutrophilia]] (at least 3 months), [[splenomegaly]], and no identifiable cause of reactive [[neutrophilia]] including the absence of a [[plasma cell neoplasm]] or, if present, demonstration of clonality of [[myeloid cells]] by [[cytogenetic]] or [[molecular]] studies. | ||
including the absence of a [[plasma cell neoplasm]] or, if present, demonstration of clonality of [[myeloid cells]] by [[cytogenetic]] or [[molecular]] studies. | |||
|} | |} | ||
| Line 60: | Line 49: | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
] | |||
[[Category:Up-To-Date]] | |||
[[Category:Medicine]] | [[Category:Medicine]] | ||
[[Category:Oncology]] | [[Category:Oncology]] | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
[[Category:Immunology]] | |||
Latest revision as of 20:57, 29 July 2020
|
Chronic neutrophilic leukemia Microchapters |
|
Differentiating Chronic neutrophilic leukemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Chronic neutrophilic leukemia diagnostic study of choice On the Web |
|
American Roentgen Ray Society Images of Chronic neutrophilic leukemia diagnostic study of choice |
|
FDA on Chronic neutrophilic leukemia diagnostic study of choice |
|
CDC on Chronic neutrophilic leukemia diagnostic study of choice |
|
Chronic neutrophilic leukemia diagnostic study of choice in the news |
|
Blogs on Chronic neutrophilic leukemia diagnostic study of choice |
|
Directions to Hospitals Treating Chronic neutrophilic leukemia |
|
Risk calculators and risk factors for Chronic neutrophilic leukemia diagnostic study of choice |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Homa Najafi, M.D.[2]; Grammar Reviewer: Natalie Harpenau, B.S.[3]
Overview
World health organization (WHO) introduces criteria for the diagnosis of chronic neutrophilic leukemia (CNL) that are based on the laboratory finding of peripheral blood cells, bone marrow, cytogenic mutation, and differential diagnosis.
Diagnostic Study of Choice
Study of choice
The diagnosis of CNL is based on the WHO criteria, which include:[1]
| World Health Organization (WHO) Criteria for CNL diagnosis | |
|---|---|
| 1. Peripheral blood White blood cells (WBC) ≥25 ×109/L: |
|
| 2. Hypercellular bone marrow: |
|
| 3. Not meeting WHO criteria for: | |
| 4. No rearrangement of: | |
|
5.Presence of CSF3RT618I or other activating CSF3R mutation or In the absence of a CSFR3R mutation, persistent neutrophilia (at least 3 months), splenomegaly, and no identifiable cause of reactive neutrophilia including the absence of a plasma cell neoplasm or, if present, demonstration of clonality of myeloid cells by cytogenetic or molecular studies. | |
References
- ↑ Arber, D. A.; Orazi, A.; Hasserjian, R.; Thiele, J.; Borowitz, M. J.; Le Beau, M. M.; Bloomfield, C. D.; Cazzola, M.; Vardiman, J. W. (2016). "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia". Blood. 127 (20): 2391–2405. doi:10.1182/blood-2016-03-643544. ISSN 0006-4971.